SIRP-gamma targeted agents for use in the treatment of cancer
AssigneeWake Forest University Health Sciences
InventorsHui-Kuan Lin, Chuan Xu, Xiu-Wu Bian, Sarah Haigh Molina, Mark Furth
Life of this patent
Estimating the term…
Abstract
Provided are methods relating to SIRPgamma as a biomarker for cancer cells, and in particular of cancer stem cells and lung adenocarcinoma. Disclosed are also methods of treatment, which involve administering a SIRPgamma targeted agent to a subject with cancer, alone or with another cancer therapy. Methods for diagnosing cancer, identifying subjects with high SIRPgamma levels for treatment, and monitoring SIRPgamma expressing tumors are also provided.
Claims13
A method of treating a subject with cancer, the method comprising administering to the subject a pharmaceutically effective amount of a composition comprising a signal-regulatory protein gamma (SIRPgamma) targeted antibody.
Dependencies are inferred from the claim text.